AZD3470用于淋巴瘤的I 期 / II 期研究｜NCT06137144

一分钟看懂

这是一项关于淋巴瘤的I 期 / II 期研究，登记的药物或干预包括AZD3470；Pembrolizumab，当前状态为招募中。登记地点显示中国北京、广州、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

AZD3470；Pembrolizumab · I 期 / II 期

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

Core Inclusion criteria:
1. Adequate adult (ECOG) or adolescent (Karnofsy or Lanksy) Performance Score assessments
2. Adequate organ and bone marrow function.
Module 1 Cohort 1:
1. Part A (dose escalation): aged ≥ 18 years at the time of signing the informed consent.
2. Part B (optimization): aged ≥ 12 years of age. Adolescent participants must weigh ≥ 40 kg.
2. Histologically confirmed diagnosis of cHL based on WHO criteria
3. Previous treatment with at least 2 prior lines of therapy for the treatment of cHL (including at least 2 cycles of BV and anti-PD1) and have documented r/r active disease requiring treatment.

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT06137144；登记信息更新于 2026-09-14。